HBsAg-Mediated TBK1 Manipulation: Interferon Suppression and Early Autophagy in HBV Infection

Study Background and Research Question

Hepatitis B virus (HBV) infection remains a significant global health concern, with an estimated 350 million chronic carriers at risk for liver disease and hepatocellular carcinoma. The HBV surface antigen (HBsAg) is central to the virus’s life cycle and immune recognition, but the precise strategies by which it modulates host innate immunity and autophagy are incompletely understood. Previous work indicated that viral proteins could interfere with pattern recognition receptor (PRR) signaling and autophagy, yet the specific crosstalk between these processes during HBV infection required clarification.

Key Innovation from the Reference Study

The reference study by Luo et al. (Cell Death and Disease, 2025) provides the first mechanistic evidence that HBsAg directly interacts with the kinase domain of TANK-binding kinase 1 (TBK1), altering its activity. This interaction enhances TBK1 dimerization and phosphorylation, but paradoxically disrupts the TBK1–IRF3 complex, thereby suppressing interferon regulatory factor 3 (IRF3) activation and subsequent type I interferon (IFN-β) production. Simultaneously, the modified TBK1 signaling promotes phosphorylation of sequestosome-1 (p62), a key autophagy regulator, resulting in the accumulation of autophagosomes. Importantly, this dual manipulation facilitates immune evasion and supports HBV persistence.

Methods and Experimental Design Insights

The study employed a combination of in vitro cell culture models, in vivo transgenic mouse systems, and ex vivo patient tissue analyses to dissect the molecular interactions between HBsAg and TBK1. Key methodologies included:

• Co-immunoprecipitation and immunoblotting to detect HBsAg–TBK1 binding, dimerization, and phosphorylation status.
• Reporter assays for IFN-β signaling and gene expression analysis of interferon-stimulated genes (ISGs).
• Confocal microscopy and biochemical fractionation to assess autophagosome accumulation and autophagic flux.
• Genetic and pharmacological inhibition using BX795, a well-characterized TBK1 inhibitor, to probe kinase-dependency of observed effects.
• Histopathological and molecular examination of liver tissues from HBsAg transgenic mice and chronic HBV patients to validate findings in physiologically relevant contexts.

Core Findings and Why They Matter

The central discoveries of Luo et al. elucidate a dual mechanism by which HBsAg manipulates host defenses:

• Suppression of Type I Interferon: Interaction of HBsAg with TBK1’s kinase domain disrupts the formation of the TBK1–IRF3 complex, preventing efficient phosphorylation and nuclear translocation of IRF3. Consequently, type I interferon induction is blunted, compromising a primary antiviral response (see study).
• Induction of Early Autophagy: HBsAg-induced TBK1 dimerization facilitates phosphorylation of p62, leading to autophagosome accumulation but impaired autophagosome–lysosome fusion. This incomplete autophagy was confirmed in both HBsAg transgenic mice and patient liver tissues, suggesting a mechanism by which HBV promotes its own replication while evading immune clearance.
• BX795 as a Dissection Tool: Use of the TBK1 inhibitor BX795 demonstrated that HBsAg-driven TBK1 dimerization and downstream effects are kinase-dependent. BX795 effectively attenuated p62 phosphorylation and autophagy induction, underscoring the centrality of TBK1 activity in this viral strategy.

Collectively, these results establish that HBsAg does not simply evade immune detection, but actively remodels kinase signaling to orchestrate a finely balanced suppression of antiviral defenses and promotion of cellular environments conducive to HBV replication. The demonstration that pharmacological TBK1 inhibition can disrupt this process opens avenues for targeted intervention.

Comparison with Existing Internal Articles

Several internal resources contextualize and extend the impact of these findings:

• BX795: Potent ATP-Competitive PDK1 and TBK1/IKKε Inhibitor details the dual specificity of BX795 as an ATP-competitive inhibitor, enabling precision modulation of the PI3K/Akt/mTOR and innate immune pathways—highly relevant given the current study’s focus on TBK1-mediated autophagy and interferon suppression.
• BX795: Novel Mechanisms in PDK1 and TBK1 Inhibition explores the intersection of autophagy and immune modulation, providing practical guidance for researchers aiming to dissect these pathways with small molecule kinase inhibitors.
• The reference study’s focus on innate immune response modulation and autophagy complements insights from Schwartz et al. regarding quantitative assessment of proliferative arrest and cell killing, underscoring the necessity of multi-parameter evaluation in antiviral and anticancer research workflows.

Together, these resources affirm the centrality of kinase pathway interrogation—using selective inhibitors like BX795—in unraveling complex viral-host interactions and signaling crosstalk.

Protocol Parameters

• BX795 concentration for TBK1/IKKε inhibition: Literature typically employs 1–2 μM in cell-based assays to achieve robust TBK1 and IKKε inhibition; always titrate for cell type and endpoint sensitivity (product information).
• Autophagy flux monitoring: Evaluate LC3-II accumulation and p62 phosphorylation in the presence and absence of lysosomal inhibitors to distinguish between autophagosome generation and degradation.
• IFN-β signaling assays: Use luciferase or qPCR-based reporters for ISG expression following poly(I:C) or LPS stimulation, with or without kinase inhibition.
• HBsAg–TBK1 interaction studies: Employ co-immunoprecipitation and site-directed mutagenesis for mapping interaction domains.
• Storage and solubility of BX795: Prepare stock solutions at ≥59 mg/mL in DMSO with gentle warming; store at –20°C, avoiding long-term storage of diluted solutions (see instructions).

Limitations and Transferability

While Luo et al. provide compelling evidence from cell lines, transgenic mice, and human tissues, certain limitations must be considered. The study primarily addresses early events in autophagy and interferon suppression; the long-term consequences for viral persistence and liver pathology require further longitudinal investigation. Additionally, pharmacological inhibitors like BX795, though highly selective, may have off-target effects that need to be accounted for in translational studies. Finally, while the findings are robust for HBV, transferability to other viral systems or to non-hepatic contexts remains to be rigorously tested.

Why this cross-domain matters, maturity, and limitations

This research highlights the intricate interplay between innate immune signaling and autophagy, domains often studied separately. By demonstrating that a viral protein can hijack a central kinase to simultaneously modify both pathways, the study bridges immunology and cell biology, suggesting new avenues for therapeutic intervention. However, the maturity of this cross-domain insight is still evolving, as most evidence is preclinical and contextual to HBV infection. Broader application to other viruses or disease models will require additional validation.

Research Support Resources

For researchers aiming to dissect kinase-mediated regulation of autophagy and interferon signaling, BX795 (SKU A8222) is available as a validated ATP-competitive inhibitor of PDK1, TBK1, and IKKε, useful for probing these pathways in vitro. Detailed assay protocols and guidance on concentration ranges can be found in the product documentation and the primary literature. APExBIO supports rigorous research applications, and BX795’s utility is well established in studies of cancer cell growth inhibition, innate immune response modulation, and autophagy research.